Nexus AG
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Nexus AG - overview
Established
1989
Location
Donaueschingen, -, Germany
Primary Industry
Software
About
Based in Germany, Nexus AG provides innovative healthcare software solutions that enhance clinical processes in hospitals and rehabilitation facilities, aiming to improve operational efficiency and patient care. Nexus AG, founded in 1989 in Donaueschingen, Germany, develops software tailored for the healthcare sector. The company has engaged in two significant deals, with the most recent occurring on November 5, 2024, involving a PIPE round that raised EUR 1. 21 billion.
The company is led by CEO Ingo Behrendt alongside a management team including Jacques Du Preez, Klaus Fritsch, René Mewes, Sebastian Muench, and Stefan Born. Nexus AG specializes in comprehensive software solutions for the healthcare sector, focusing on hospitals and rehabilitation institutions. Their flagship product, NEXUS / HIS NG, is a hospital information system that streamlines clinical processes across departments. Additionally, NEXUS / LAB offers software for laboratory diagnostics in fields like pathology and cytology.
Their solutions include digital pathology and teleradiology systems, catering primarily to the European market's healthcare professionals. In the most recent year of 2022, Nexus AG reported a revenue of EUR 220. 38 mn and an EBITDA of EUR 46. 67 mn.
Revenue is generated through software license sales and service subscriptions, primarily targeting B2B transactions with healthcare institutions requiring specialized IT solutions. Following the recent PIPE funding round on November 5, 2024, which raised EUR 1. 21 billion, Nexus AG plans to expand its market reach across Europe. This capital will be utilized to support the development of new products and to enhance their operational capabilities.
The firm aims to introduce innovative software solutions designed to improve clinical workflows in healthcare facilities. Additionally, plans are in place to explore new geographic markets, particularly within the European Union, to further enhance their service offerings and customer base.
Current Investors
Luxempart, TA Associates
Primary Industry
Software
Sub Industries
Medical Software
Website
www.nexus-ehealth.com/
Verticals
Mobile Apps
Company Stage
Mature
Total Amount Raised
Subscriber access only
Nexus AG - timeline of key events
Nexus AG - financials
| Fiscal Year Ended | Dec 31, 2010 | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 44,823,000 | 53,534,000 | 62,340,000 | 73,263,000 | 80,147,000 | 97,269,000 | 107,051,000 | 119,083,000 | 136,469,000 | 147,648,000 | 162,944,000 | 188,178,000 | - | - | - |
| % Revenue Growth (YoY) | - | 19.4% | 16.4% | 17.5% | 9.4% | 21.4% | 10.1% | 11.2% | 14.6% | 8.2% | 10.4% | 15.5% | - | - | - |
| EBITDA (USD) | 9,449,000 | 10,627,000 | 11,901,000 | 13,998,000 | 15,044,000 | 18,883,000 | 21,018,000 | 23,721,000 | 26,708,000 | 33,947,000 | 36,640,000 | 40,770,000 | - | - | - |
| Operating Income (USD) | 3,730,000 | 4,219,000 | 5,402,000 | 6,920,000 | 8,031,000 | 9,640,000 | 10,926,000 | 13,319,000 | 15,181,000 | 17,444,000 | 19,915,000 | 24,114,000 | - | - | - |
| Operating Margin | 8.3% | 7.9% | 8.7% | 9.4% | 10.0% | 9.9% | 10.2% | 11.2% | 11.1% | 11.8% | 12.2% | 12.8% | - | - | - |
| % EBITDA Margin | 21.1% | 19.9% | 19.1% | 19.1% | 18.8% | 19.4% | 19.6% | 19.9% | 19.6% | 23.0% | 22.5% | 21.7% | - | - | - |
| NET Income (USD) | 3,538,000 | 4,695,000 | 5,762,000 | 7,220,000 | 8,108,000 | 7,777,000 | 8,611,000 | 10,156,000 | 10,996,000 | 12,121,000 | 15,091,000 | 17,459,000 | - | - | - |
| % Net Margin | 7.9% | 8.8% | 9.2% | 9.9% | 10.1% | 8.0% | 8.0% | 8.5% | 8.1% | 8.2% | 9.3% | 9.3% | - | - | - |
Nexus AG - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on, Trade Sale | Announced | Omilon AS | - | ||||||||
| PIPE | Completed | Nexus AG | - | ||||||||
| Add-on, LP Direct | Completed | HD Clinical Limited | - | ||||||||
| LP Direct, PIPE | Completed | Nexus AG | - | ||||||||
| Trade Sale | Completed | RVC Medical IT B.V. | - |
Displaying 1 - 5 of 5
Nexus AG - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.